Company overview
Founded in May 2017 and based at the Babraham Research Campus in Cambridge, PredictImmune develops pioneering tools for guiding treatment options in immune-mediated inflammatory diseases like Crohn’s and ulcerative colitis (IBD).
Based on ten years of research at Cambridge University, PredictImmune’s test kits help both clinicians and patients to understand, at the point of diagnosis, the likely course of disease and opens the possibility of better treatment choices from the outset.
Website
PredictImmuneCompany information
Head office
- Cambridge
CEO
- Paul Kinnon
Chair
- Andrew P Sandham
BGF office
BGF team
Investment date
- Jul 2019
Total BGF investment
- £4 million
